AlphaStocks

ABBV vs REGN

As of Sep 20, 2026, AbbVie (ABBV) scores 7.8/10 and Regeneron Pharmaceuticals (REGN) 5.4/10 on AlphaStocks' five-model composite, so ABBV scores higher. ABBV trades 102% above its model fair value; REGN trades 33% below its model fair value.

ABBV

AbbVie Inc.

7.8

Strong Buy

$263.86

REGN

REGENERON PHARMACEUTICALS, INC.

5.4

Consider Buy

$784.95

ABBV vs REGN: Which is the Better Investment?

AbbVie Inc. (ABBV) scores 7.8/10 while REGENERON PHARMACEUTICALS, INC. (REGN) scores 5.4/10 on AlphaStocks' composite model. AbbVie Inc. has the higher composite rating of Strong Buy. On a P/E basis, REGENERON PHARMACEUTICALS, INC. trades at 18.9x, making it the more attractively priced of the two. REGENERON PHARMACEUTICALS, INC. trades further below its estimated fair value.

This comparison is algorithmically generated and is not financial advice.

MetricABBVREGN
Scores & Fundamentals
Composite Score7.8/105.4/10
RatingStrong BuyConsider Buy
Price$263.86$784.95
P/E Ratio110.718.9
ROE-143.0%12.7%
Market Cap$468B$85B
Fair Value$130.53$1,175.19
Dividend Yield2.7%0.5%
Sector Rank#2 of 168#82 of 168
Model Verdicts
PiotroskiStrongAttractive
BuffettStrongAttractive
GrahamNeutralNeutral
LynchNeutralAttractive
GreenblattNeutralNeutral
View full ABBVanalysis →View full REGNanalysis →

Related comparisons

Compare any two stocks →

ABBV vs REGN: Which Stock Scores Higher?

AbbVie Inc. (ABBV) and REGENERON PHARMACEUTICALS, INC. (REGN) are both in the Health Care sector. ABBV currently leads with a composite score of 7.8/10 (Strong Buy) compared to REGN's 5.4/10 (Consider Buy).

The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.

This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer